|1.||Xu, Jianming: 23 articles (08/2015 - 06/2002)|
|2.||O'Malley, Bert W: 22 articles (08/2015 - 12/2002)|
|3.||Liao, Lan: 9 articles (08/2015 - 06/2002)|
|4.||Lonard, David M: 8 articles (08/2015 - 01/2006)|
|5.||Jeschke, Udo: 8 articles (04/2015 - 05/2005)|
|6.||Sasano, Hironobu: 8 articles (11/2011 - 05/2003)|
|7.||Auricchio, Ferdinando: 7 articles (01/2012 - 11/2005)|
|8.||Migliaccio, Antimo: 7 articles (01/2012 - 11/2005)|
|9.||Castoria, Gabriella: 7 articles (01/2012 - 11/2005)|
|10.||Mylonas, Ioannis: 7 articles (05/2010 - 05/2005)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/2005 - "Targeting the ability of steroid receptors to activate MAPKs may be beneficial for breast cancer patients."
09/01/1995 - "Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation."
07/01/1990 - "Site of first recurrence, disease-free interval (DFI), female sex steroid receptors, ploidy measurements as well as histological grading have been analysed as potentially valuable predictive factors in 313 cases of recurrent breast cancer. "
01/01/2008 - "Bag-1 and Bcl-2 expression in breast tumors is associated with improved outcome and steroid receptor positivity. "
07/01/1990 - "Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading."
12/01/1990 - "Treatment with CMF resulted in a significant improvement in RFS in premenopausal patients both with steroid receptor-positive and steroid receptor-negative tumors and also in subgroups of premenopausal patients defined by the number of axillary nodes involved. "
06/07/2000 - "Patients with steroid receptor-negative tumors or with tumors of unknown receptor status who had a disease-free interval of less than 2 years were excluded. "
01/01/1982 - "These results suggest that repeat steroid receptor assays on accessible tumor immediately before endocrine therapy may result in improved predictability."
12/01/2013 - "Overexpression of steroid receptor coactivator-3 in bone cancers: an in vivo immunohistochemical study with tissue microarray."
01/01/2012 - "An immunohistochemical study on the expression of sex steroid receptors in canine mammary tumors."
|3.||Endometrial Neoplasms (Endometrial Cancer)
03/01/2003 - "The efficacy of novel drugs targeting steroid receptors in endometrial cancers has to be evaluated and the safety of other endocrine measures on endometrial cancers or on endometrial carcinogenesis has to be assessed. "
11/15/2003 - "The current study showed that expression levels of the steroid receptor coactivators SRC-1 and p300/CBP were reduced in endometrial carcinoma compared with normal and hyperplastic endometrium. "
01/01/2000 - "Endometrial cancer in elderly women: A histologic and steroid receptor study."
06/01/1990 - "The aim of this study was to evaluate tissue and steroid receptor heterogeneity in endometrial carcinoma specimens as a possible source of discordance between biochemically assayed receptor status and response to endocrine treatment. "
01/01/1987 - "Steroid receptors and human endometrial carcinoma: studies in a nude mouse model."
|4.||Prostatic Neoplasms (Prostate Cancer)
03/06/2014 - "Steroid receptors aplenty in prostate cancer."
02/01/2014 - "Although reactivation of steroid receptors likely plays a pivotal role in aggressive CRPC, little is understood regarding the mechanisms whereby prostate cancer cells initiate and maintain steroidogenesis. "
01/01/2014 - "The steroid receptor coactivator-1 (SRC-1) is highly expressed in breast, endometrial, and prostate cancer. "
01/15/2012 - "Overall, our data validate the concept of dual AR/GR targeting in prostate cancer (PC) and suggest that BZ combination with dual-target steroid receptor modulator CpdA has high potential for PC therapy."
01/01/2012 - "Targeting rapid action of sex-steroid receptors in breast and prostate cancers."
|5.||Ovarian Neoplasms (Ovarian Cancer)
01/01/1986 - "Future progress in the application of female sex steroid receptor analyses in breast, endometrial and ovarian cancer needs additional controlled clinical trials and more highly developed receptor assays."
08/01/2014 - "Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. "
06/01/2013 - "The steroid receptor coactivator p/CIP, also known as SRC-3, is an oncogene commonly amplified in breast and ovarian cancers. "
01/01/2011 - "The data collectively indicate that functional steroid receptors are required in steroid up-regulation of p66Shc protein levels in prostate and ovarian cancer cells, correlating with cell proliferation. "
10/01/2009 - "Forty-three had serous papillary ovarian cancer, 9 of which were grade I, 12 grade II and 2 grade III. Twelve patients had a classic mucinous ovarian cancer, 5 of which were grade I, 4 grade II and 0 grade III. Out of 43 patients with serous ovarian cancer, 7 expressed both steroid receptors, 22 had only one (10 ER and 12 PR), while 14 were negative. "
|4.||DNA (Deoxyribonucleic Acid)
|5.||Proteins (Proteins, Gene)
|6.||Epidermal Growth Factor Receptor (EGF Receptor)
|8.||Androgen Receptors (Androgen Receptor)
|9.||Estrogen Receptor Modulators (Antiestrogen)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Hormone Replacement Therapy (Therapy, Hormone Replacement)